Blood and Marrow Transplant Clinical Trials Network

血液和骨髓移植临床试验网络

• 批准号: 8174290
• 负责人: JOANNE KURTZBERG
• 金额: $ 15.54万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-30 至 2017-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8174290
• 关键词: Academic Medical Centers; Acute; Adult; Adverse event; Antigens; Attention; Blood; Blood Banks; Caring; Cells; Childhood; Classification; Clinical; Clinical Investigator; Clinical Trials; Clinical Trials Design; Clinical Trials Network; Coin; Collaborations; Colony-forming units; Communication; Consensus; Controlled Clinical Trials; Cryopreservation; Data; Data Coordinating Center; Data Reporting; Discipline; Disease; Dose; Engraftment; Enrollment; Exhibits; Foundations; Future; Goals; Guidelines; Hematopoietic Stem Cell Transplantation; Immune; Incidence; Infection; Instruction; Investigation; Malignant - descriptor; Malignant Neoplasms; Manuscripts; Marrow; Mission; Multicenter Studies; Multicenter Trials; National Heart, Lung, and Blood Institute; Non-Malignant; Outcome; Patient Selection; Patients; Phase; Phase III Clinical Trials; Population; Positioning Attribute; Practice Management; Preparation; Principal Investigator; Probability; Process; Prophylactic treatment; Protocols documentation; Randomized; Rare Diseases; Registries; Research Personnel; Research Proposals; Retrospective Studies; Role; Safety; Specimen; Standardization; Structure; Supportive care; System; Testing; TimeLine; Transplant Recipients; Transplantation; Treatment Protocols; Umbilical Cord Blood; Umbilical Cord Blood Transplantation; Validation; Work; base; chronic graft versus host disease; clinical care; clinical practice; common treatment; conditioning; design; disorder risk; experience; forging; graft failure; graft vs host disease; immunoprophylaxis; improved; international center; meetings; patient population; pre-clinical; programs; prospective; randomized trial; reconstitution; success; symposium

DESCRIPTION (provided by applicant): The pediatric and adult transplant programs at Duke University Medical Center have served as a core clinical center for the BMT-CTN since its establishment in 2001. As a core center, Duke has made significant contributions to the network, including enrollment of 117 patients on CTN protocols, chairing two protocols (Dr. Kurtzberg chairs 0501 and Dr. Horwitz chairs 0901); serving on 6 protocol committees and 2 disease committees, authoring manuscripts and establishing and managing the immune reconstitution core for protocol 0501. The center has been in compliance with accurate and timely data and bio-specimen submission. The PI and Co-PI have regularly attended steering committee meetings and conference calls. Duke brings two specialized types of expertise to the CTN, (1) a long-standing and pioneering role in cord blood transplantation and banking and (2) unique experience in the treatment of pediatric patients with hematopoietic stem cell transplantation for non-malignant diseases. The study concept proposed in this application, based on ongoing work at Duke, will serve as the foundation for a follow-on study to BMT-CTN 0501. It is focused on furthering the understanding of the mechanisms that underlie engraftment after UCBT. Through analyses of banking (from the Carolinas Cord Blood Bank) and transplant outcomes at Duke, we have shown that dosing of colony forming units (CFUs) in thawed cord blood units best correlates with engraftment. Further analyses of additional parameters characterizing cord blood units before cryopreservation and after thawing allowed us to develop a predictive scoring system, coined the "cord blood apgar" (CBA) which, in a retrospective validation, most accurately determines cord blood potency and most closely correlates with engraftment potential. We propose to test and prospectively validate the CBA to optimize CBU selection in patients undergoing UCBT. The overarching goal of this work is to reduce engraftment delays and rates of primary graft failure after UCBT, increasing the overall success of UCBT. RELEVANCE (See instructions): The BMT-CTN is a highly important network of transplant centers working together to identify best practices and best therapies for patients with malignant and non-malignant diseases treated with transplantation. Duke has participated in the CTN since 2001 and has contributed significantly to its mission. The research proposal in this application will increase safety and efficacy of cord blood transplantation.

描述（由申请人提供）：自2001年成立以来，杜克大学医学中心的儿科和成人移植项目一直是BMT-CTN的核心临床中心。作为核心中心，杜克为该网络做出了重大贡献，包括根据CTN方案招募了117名患者，主持了两项方案（Kurtzberg博士主持0501和Horwitz博士主持0901）;在6个方案委员会和2个疾病委员会任职，撰写手稿，建立和管理方案0501的免疫重建核心。中心一直遵守准确和及时的数据和生物标本提交。主要研究者和共同主要研究者定期出席指导委员会会议和电话会议。杜克为CTN带来了两种专业知识，（1）在脐带血移植和库中的长期和开创性作用，以及（2）在治疗非恶性疾病的造血干细胞移植儿科患者方面的独特经验。基于杜克正在进行的工作，本申请中提出的研究概念将作为BMT-CTN 0501后续研究的基础。它的重点是进一步了解UCBT后植入的机制。通过分析库（来自哥伦比亚脐带血库）和杜克的移植结果，我们已经表明解冻脐带血单位中的集落形成单位（CFU）的剂量与植入最相关。进一步分析表征脐带血单位冷冻保存前和解冻后的其他参数，使我们能够开发一种预测评分系统，创造了“脐带血阿氏评分”（CBA），在回顾性验证中，最准确地确定脐带血效价，并与植入潜力最密切相关。我们建议测试并前瞻性验证CBA，以优化接受UCBT的患者的CBU选择。这项工作的总体目标是减少UCBT后的植活延迟和原发性移植失败率，提高UCBT的总体成功率。相关性（参见说明）：BMT-CTN是一个非常重要的移植中心网络，共同努力为接受移植治疗的恶性和非恶性疾病患者确定最佳实践和最佳疗法。杜克自2001年以来一直参与CTN，并为其使命做出了重大贡献。本申请的研究方案将提高脐带血移植的安全性和有效性。